11/11
10:22 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
11/11
08:18 am
dnth
Rating for DNTH
High
Report
Rating for DNTH
11/11
08:18 am
dnth
Rating for DNTH
High
Report
Rating for DNTH
11/8
12:43 pm
dnth
Rating for DNTH
Low
Report
Rating for DNTH
11/8
12:43 pm
dnth
Rating for DNTH
Low
Report
Rating for DNTH
10/3
08:17 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $48.00 price target on the stock.
Medium
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $48.00 price target on the stock.
10/3
08:05 am
dnth
Rating for DNTH
Medium
Report
Rating for DNTH
10/3
08:05 am
dnth
Rating for DNTH
Medium
Report
Rating for DNTH
9/26
08:17 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.